Overview

To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2001-06-01
Target enrollment:
Participant gender:
Summary
To demonstrate the relative bioavailability of Metformin HCl 500 mg XR tablets under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Sandoz
Treatments:
Metformin